Flavanol–ε-Viniferin Monomer Composition for Endothelial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current products are inadequate in effectively preventing or treating endothelial dysfunction and associated diseases, sleep disorders, stress, cognition, and sun protection, with a need for improved efficacy compared to existing molecules.
Innovation Solution
A composition comprising a specific combination of flavanol monomers and ε-viniferine, derived from Vitis vinifera, in a ratio of 20,000 to 4, exhibits a synergistic effect, enhancing endothelial function and providing antioxidant, UV protection, and cognitive benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single molecules (flavanol monomers or ε-viniferine) are used individually, then the product is simple to manufacture and administer, but the efficacy in improving endothelial function is insufficient
Solution Approach 1:
The patent combines flavanol monomers and ε-viniferine into a single composition to achieve synergistic effects that improve endothelial function beyond what either molecule can accomplish alone. The merging of these two active ingredients creates a composite product with enhanced therapeutic efficacy for preventing and treating endothelial dysfunction and associated diseases.
Solution Approach 2:
The invention creates a composite composition comprising both flavanol monomers and ε-viniferine, where the combination of different molecular structures and mechanisms of action produces a synergistic effect. This composite approach allows the product to leverage the vasodilatory properties of flavanols and the antioxidant/anti-inflammatory properties of ε-viniferine simultaneously.
2Reliability
If higher doses of flavanol monomers are used to improve cognitive functions, then cognitive benefits increase, but the cost of production and administration increases
Solution Approach 1:
By combining flavanol monomers with ε-viniferine in a synergistic composition, the patent achieves enhanced cognitive benefits at potentially lower doses than would be required for flavanol monomers alone. The synergistic interaction between the two molecules amplifies the therapeutic effect, allowing for reduced quantity of active ingredients while maintaining or improving efficacy.
Data Source
Figure 1~2B
Figure 3~4
AI summary
The present invention relates to a composition comprising the association of the molecules of flavanol and epsilon-viniferin monomers as a nutritional product or a drug for humans or animals.